Anticancer Drug Discovery Based on Plant Biodiversity (Abstract)

Hongjie Zhang, Kanglun Liu, Yifu Guan

Research output: Contribution to journalConference articlepeer-review


Contrary to the mainstream compound library screening established by pharmaceutical companies, our studies focus on natural products for discovery of potent biologically active agents from thousands of plant extracts. The advantage of screening natural products is that the chemical space covered by natural products is much more diversified, which is considered as a key to successful drug discovery research. By participating in several multi-disciplinary cooperative programs, we had an opportunity to access a sample library containing more than 6,000 plant extracts. Through evaluation of cell killing activity of the sample library against a panel of human cancer cell lines, we have already discovered 370 active plant leads, including 44 with an IC50 value of less than 1 μg/ml, 45 with an IC50 value in the range of 1-3 μg/ml, 55 with an IC50 value in the range of 3-5 μg/ml and 138 with an IC50 value in the range of 10-20 μg/ml. The plant extracts were derived from 229 plant species in 88 families, which were collected from Southeastern Asia countries including China, Vietnam and Laos. Bioassayguided fractionation of several prioritized active plant extracts led to the isolation and identification of a series of potent anticancer compounds. Among these active compounds, several have demonstrated potent anticancer activity both in in vitro and in vivo studies.
Original languageEnglish
Pages (from-to)6253-6254
Number of pages2
JournalAnticancer Research
Issue number10
Publication statusPublished - 6 Oct 2014
Event9th International Conference on Cancer Research, ICCR 2014 - Sithonia, Greece
Duration: 6 Oct 201410 Oct 2014 (Book of abstracts)


Dive into the research topics of 'Anticancer Drug Discovery Based on Plant Biodiversity (Abstract)'. Together they form a unique fingerprint.

Cite this